Avoid products marketed as curing myopia or restoring the prescription to normal
China's market regulator states that current medical technology cannot cure myopia. Its enforcement notice targets misleading promises of recovery, reduced prescription, a myopia cure, or repaired vision. Do not let such language substitute for evidence. Platforms selling regulated eye-care devices must check the sellers' qualifications.
What it takes
Avoiding misleading products saves money.
What you may gain
A State Administration for Market Regulation campaign running from November 2021 to March 2022 stated that myopia cannot currently be cured. It called for strict action against misleading marketing terms including rehabilitation, recovery, reduced diopters, myopia cure, “myopia nemesis,” and prescription repair. It also targeted deceptive use of traditional Chinese medicine labels or theories and unlawful advertisements using patients' identities or images for before-and-after comparisons or guaranteeing treatment safety or efficacy. E-commerce platforms were required to check qualifications for eye-care devices regulated as medical devices and other special-category products. These are Chinese enforcement rules.
Context & considerations
Evidence is B because this is the regulator's enforcement position rather than a controlled product trial. Health guidance similarly describes myopia as preventable and controllable but irreversible. See entry 4 for outdoor activity and entry 12 for proper assessment, correction, and follow-up. For blue-light-blocking glasses, see chapter 6.
Research & references
General Office of the State Administration for Market Regulation (2021). Notice on a special campaign against unlawful marketing of childhood and adolescent myopia prevention and control products. https://www.gov.cn/zhengce/zhengceku/2021-11/12/content_5650400.htm